Catheter Precision, Inc.: approves 5,000,000 share increase to 2023 equity plan

What happened

• Catheter Precision, Inc. filed an 8-K reporting that at its annual meeting on Sep 30, 2026 stockholders approved an amendment to the Company’s 2023 Equity Incentive Plan to increase the number of shares reserved for issuance by 5,000,000 shares, and approved a one-time repricing of outstanding stock options with exercise prices greater than Fair Market Value to equal Fair Market Value. The filing states the Fair Market Value based on the closing price on the NYSE American on Sep 30, 2026 was $0.152 per share, and that the 1-for-10 reverse stock split of the Common Stock will become effective at 12:01 a.m. Eastern Time on Oct 5, 2026.

Key details

• Record date and voting: of 18,972,049 shares outstanding as of Aug 18, 2026, 12,343,463 shares were represented at the meeting (approximately 65.1%).
• Proposal votes: Proposal No. 5 (2023 plan increase) was approved with 8,922,384 votes for, 920,369 votes against, 99,010 abstentions and 2,401,700 broker non-votes; Proposal No. 6 (one-time repricing) was approved with 9,006,036 votes for, 802,658 votes against, 133,070 abstentions and 2,401,699 broker non-votes.
• Option specifics: the Repricing did not change the number of shares subject to any option, its expiration date or its vesting schedule. The filing lists repriced options of 89,999 shares held by David A. Jenkins and 66,315 shares held by Philip Anderson, each as of Aug 18, 2026. After the 1-for-10 reverse stock split, the exercise price of each repriced option will be $1.52 per share.

Why it may matter

• Item 5.02 of the filing covers the amendment to the 2023 Equity Incentive Plan and the one-time repricing of outstanding stock options; Item 5.03 reports the 1-for-10 reverse stock split becoming effective Oct 5, 2026; Item 5.07 reports the vote totals from the Sep 30, 2026 annual meeting. This filing does not show why the insider traded or why the company acted.